Homologous Recombination Deficiency, Genetics, PARP Inhibitors, and Screening in Cancer

Authors

Amy Bodrog, Rochester Regional HealthFollow

Document Type

Presentation

Department

Oncology and Hematology

Abstract

Homologous Recombination Deficiency, Genetics, PARP Inhibitors, and Screening in Cancer, Amy Bodrog, MD, Lipson Cancer Institute

Objectives:

• Discuss how PARP inhibitors work.
• Discuss when screening for homologous recombination deficiency is appropriate.

Publication Date

10-19-2023

Recommended Citation

Bodrog, A. (2023). Homologous Recombination Deficiency, Genetics, PARP Inhibitors, and Screening in Cancer. Retrieved from https://scholar.rochesterregional.org/grandrounds_rgh/102